#USA #New York #Faruqi & Faruqi #stock decline #Altimmune

Investor Alert: Investigation into Altimmune's Stock Decline

Faruqi & Faruqi, LLP, a prominent national securities law firm, has announced its investigation into potential claims on behalf of investors of Altimmune, Inc., amid serious concerns regarding its stock performance and ongoing class action litigation. As per their announcements, investors who purchased or acquired securities in Altimmune between August 10, 2023, and June 25, 2025, are experiencing noteworthy losses that warrant legal attention.

Background on the Situation

On June 26, 2025, following the announcement of disappointing clinical trial results, Altimmune's stock took an unprecedented hit. The company's press release detailed the topline results from the Phase 2b MASH trial of Pemvidutide, which aimed to address Non-Alcoholic Steatohepatitis (NASH). Despite the company's initial promises and expectations regarding positive outcomes, the trial results demonstrated a significant failure to achieve statistical significance in measuring fibrosis reduction.

As investors hold various concerns regarding the integrity of the information provided by Altimmune, the firm’s lead partner, James (Josh) Wilson, has encouraged affected individuals to reach out to discuss their legal rights. Notably, following the release of the trial results, the stock plummeted dramatically from $7.71 to $3.61—a staggering 53.2% decline in a single trading day.

Understanding the Legal Landscape

In the context of securities class actions, investors are advised to participate actively. The deadline looming for this particular case is October 6, 2025, by which time investors must express their desire to serve as lead plaintiffs. The lead plaintiff is often the individual who suffered the greatest financial loss who is also capable of directing the litigation, representing the interests of the entire affected class.

By becoming involved in this class action, investors may secure a share of any potential financial recovery in the event of a favorable outcome from the litigation. However, there is also an alternative route for potential plaintiffs as well: they can choose to remain passive members of the class without undertaking any responsibilities or obligations.

The Path Forward

Faruqi & Faruqi encourages any individuals holding pertinent information about Altimmune's practices to reach out, especially whistleblowers, shareholders, or former employees. Such insights might prove invaluable in constructing a robust case. For those considering legal action, the opportunity for dialogue with Faruqi & Faruqi's experienced professionals is available through direct contact at the numbers provided in their announcements.

Stay Informed

As this case develops, it is essential for investors to stay connected with updates from Faruqi & Faruqi. The law firm maintains a presence on various platforms, including LinkedIn and Facebook, where they offer continual insights on current progress and related legal matters.

In conclusion, investors holding securities in Altimmune have a critical decision deadline approaching in this challenging landscape. Faruqi & Faruqi stands ready to assist those who have faced financial setbacks connected to this significant decline in stock value, ensuring that investor interests remain protected during these turbulent times.

For thorough information regarding the ongoing class action against Altimmune, visit the law firm’s official site or contact them directly to ensure your rights and interests are safeguarded.